JAN 2 5: 2007 2

Modified Form 1449/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Application Number	10/626,356 July 24, 2003		
Filing Date			
First Named Inventor	Michael Hale et al.		
Group Art Unit	1626		
Examiner Name	Rebecca L. Anderson		
Attorney Docket Number	VPI/00-122 DIV2 US		

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Publication Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS					
Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No

OTHER NON PATENT LITERATURE DOCUMENTS					
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.			
/RA/	C9	Chang, et al., "Role of cAMP-Dependent Pathway in Eosinophil Apoptosis and Survival," Cellular Immunology; 203;29-38 (2000).			
/RA/	C10	Frey and Mulder, "TGFB regulation of mitogen-activated protein kinases in human breast cancer cells," Cancer Letters, 117:41-50 (1997).			
/RA/	CII	Fukunaga and Miyamoto, "Role of MAP Kinase in Neurons," Molecular Neurobiology, 16(1):79-95 (1998).			
/RA/	C12	Hoshino, et al., "Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors," Oncogene, 18:813-822 (1999).			
/RA/	C13	Illenberger, et al., "The Endogenous and Cell Cycle-dependent Phosphorylation of tau Protein in Living Cells: Implications for Alzheimer's Disease," Molecular Biology of the Cell, 9:1495-1512 (June 1998).			
/RA/	C14	Kodama, et al., "Significance of ERK cascade compared with JAK/STAT and PI3-K pathway in gp130-mediated cardiac hypertrophy," Am. J. Physiol Heart Circ Physiol, 279:H1635-H1644, (2000).			
/RA/	C15	Kortylewski, et al., "Mitogen-activated protein kinases control p27/Kip1 expression and growth of human melanoma cells," Biochem J., 357:297-303, (2001).			
/RA/	CI6	Namura, et al., "Intravenous administration of MEK inhibitor U0126 affords brain protection against forebrain ischemia and focal cerebral ischemia," PNAS, 98(20);11569-11574 (September 25, 2001).			
/RA/	C17	Putz, et al., "Epidermal Growth Factor (EGF) Receptor Blockade Inhibits the Action of EGF, Insulin-like Growth Factor I, and a Protein Kinase A Activator on the Mitogen-activated Protein Kinase Pathway in Prostate Cancer Cell Lines," Cancer Research, 59:227-233 (January 1, 1999).			
/RA/	C18	Raghunandan and Ingram, "Hyperphosphorylation of the Cytoskeletal Protein Tau by the MAP-Kinase PK40erk2: Regulation by Prior Phosphorylation with cAMP-Dependent Protein Kinase A," Biochemical and Biophysical Research Communications, 215(3);1056-1066, (October 24, 1995).			
/RA/	C19	Slevin, et al., "Activation of MAP kinase (ERK-1/ERK-2), tyrosine kinase and VEGF in the human brain following acute ischaemic stroke," NeuroReport, 11(12);2759-2764 (August 21 2000).			

a copy or time	reference is not provided as it was previously	cited by or submitted to the office in	n a prior application,		
U.S.S.N		, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation,			
continuation-in-part, and divisional applications).					
Examiner Signature	/Rebecca Anderson/	Date Considered	03/14/2007		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.